about
Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of actionAdrenocorticotropic hormone versus methylprednisolone added to interferon β in patients with multiple sclerosis experiencing breakthrough disease: a randomized, rater-blinded trialSerum metabolomic response of myasthenia gravis patients to chronic prednisone treatment.The multiple sclerosis relapse experience: patient-reported outcomes from the North American Research Committee on Multiple Sclerosis (NARCOMS) RegistryIslamic fasting and multiple sclerosis.Females uniquely vulnerable to alcohol-induced neurotoxicity show altered glucocorticoid signaling.A predictive model for corticosteroid response in individual patients with MS relapsesDeferiprone modulates in vitro responses by peripheral blood T cells from control and relapsing-remitting multiple sclerosis subjects.Immune mediated diseases and immune modulation in the neurocritical care unitAKP-11 - A Novel S1P1 Agonist with Favorable Safety Profile Attenuates Experimental Autoimmune Encephalomyelitis in Rat Model of Multiple SclerosisReprogrammed quiescent B cells provide an effective cellular therapy against chronic experimental autoimmune encephalomyelitis.Multidisciplinary rehabilitation and steroids in the management of multiple sclerosis relapses: a randomized controlled trialH.P. Acthar Gel (repository corticotropin injection) treatment of patients with multiple sclerosis and diabetesMultiple Sclerosis: Immunopathology and Treatment Update.Distribution of corticosteroid receptors in mature oligodendrocytes and oligodendrocyte progenitors of the adult mouse brain.The Norwegian Multiple Sclerosis Registry and Biobank.
P2860
Q26822611-5683599E-7B1E-4368-9B7E-0B468147D32FQ33589934-F5362E47-5F6F-4E14-84DB-3DB85FDA0F5AQ33916520-360F8141-0E3C-4432-85A4-5EA400689ACAQ34982119-85FA9A27-8D00-41E0-841F-FB3944B30ADBQ35127335-FADB7A64-9219-4857-918A-514E7B3A987DQ35184582-0031332A-8917-43A6-8330-95991F62B82BQ35192482-CEBD6AD2-D388-4EE1-934C-8796B0D12855Q35476281-6D1B4A93-35C4-42B9-8D6D-FEAA3E15BAA5Q35729575-D150EA1E-9090-4AEF-994D-077B54BBA74DQ35826151-010956AF-542E-405B-888D-133D736ACA81Q36201277-FB8592AA-08DB-4AC0-9C8D-54492736CB01Q36845247-A6B1BFF2-B114-4985-B884-5D55517B5047Q37072620-42DA2CF4-C92E-4354-BD79-E70FECA59427Q39420793-124FE0F7-3D4E-4031-89D2-9F58E854609BQ41979696-6CCCE447-5156-42C1-BF49-4551D66882E7Q44489999-235B1B3E-DE6F-463A-B32C-88AAA70CB393
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Corticosteroids in the treatment of multiple sclerosis.
@en
Corticosteroids in the treatment of multiple sclerosis.
@nl
type
label
Corticosteroids in the treatment of multiple sclerosis.
@en
Corticosteroids in the treatment of multiple sclerosis.
@nl
prefLabel
Corticosteroids in the treatment of multiple sclerosis.
@en
Corticosteroids in the treatment of multiple sclerosis.
@nl
P2860
P1476
Corticosteroids in the treatment of multiple sclerosis.
@en
P2093
S I Mellgren
P2860
P356
10.1111/J.1600-0404.2009.01213.X
P577
2009-01-01T00:00:00Z